NCT06086496View on ClinicalTrials.gov

Effectiveness and Safety of Abluminal Biodegradable Polymer Sirolimus-eluting Stent (GENOSS® DES)

Enrolling by invitationOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Coronary Artery DiseasePercutaneous Coronary Intervention
Interventions
DEVICE

GENOSS® DES Sirolimus Eluting Coronary Stent System

The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Trial Locations (1)

Unknown

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Genoss Co., Ltd.

INDUSTRY